IN8bio appoints Dr. Corinne Epperly to Board, adopts amended bylaws

IN8BIO, INC.

Board expanded to 8 directors; Dr. Epperly appointed as Class II director effective Dec 6, 2023, term through 2026 annual meeting.
Dr. Epperly to serve on Compensation and Science & Technology Committees; former COO of Cargo Therapeutics and SVP at Iovance.
Bylaws amended to comply with universal proxy rules (Rule 14a-19), enhance stockholder nominee disclosures, and adopt DGCL updates.
Non-employee director compensation policy updated Dec 5, 2023: annual cash retainer $40k, initial option grant 54,800 shares, annual grant 27,400 shares.

item 5.02 item 5.03 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Corinne Epperly

Class II Director

INAB · IN8BIO, INC.

Effective: 2023-12-06
Filed: December 7, 2023, 6:59 PM ET

appointed Corinne Epperly, M.D., as a Class II director of the Company

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Corinne Epperly was appointed as Class II Director at IN8BIO, INC..

Action: appointed
Role: Class II Director

Exact text from the filing

appointed Corinne Epperly, M.D., as a Class II director of the Company

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

IN8BIO, INC.: Board approved and adopted Second Amended and Restated Bylaws with changes addressing universal proxy rules, advance notice requirements, and other updates (effective 2023-12-06).

Change: bylaw amendment
Effective: 2023-12-06

Exact text from the filing

On December 6, 2023, the Board approved and adopted the Second Amended and Restated Bylaws of the Company (the “Amended Bylaws”), which became effective immediately.

View on SEC.gov

59 governance changes filed in the last 30 days. Browse all governance changes →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0001193125-23-290707

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.